Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Million
VICTORIA, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has priced its previously announced overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”). Pursuant to the Offering, Eupraxia will issue 7,317,000 Shares at a price of C$4.10 per Share for gross proceeds of C$30 million.
- Pursuant to the Offering, Eupraxia will issue 7,317,000 Shares at a price of C$4.10 per Share for gross proceeds of C$30 million.
- The Offering is being conducted pursuant to the terms and conditions of an underwriting agreement between the Company and Raymond James Ltd. as sole underwriter and bookrunner (the “Underwriting Agreement”).
- Closing of the Offering is subject to a number of customary conditions, including approval of the Toronto Stock Exchange.
- The Offering will be made in Canada only by means of the base shelf prospectus and prospectus supplement.